Antibody fragment-targeted immunoliposomes for systemic gene delivery
AssigneesSynerGene Therapeutics, Inc., Georgetown University
InventorsLiang Xu, Cheng-Cheng Huang, William Alexander, WenHua Tang, Esther H. Chang
Life of this patent
Estimating the term…
Abstract
Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.
Claims14
A nucleic acid-cationic immunoliposome complex comprising i) a cationic liposome, ii) an scFv antibody fragment, and iii) a nucleic acid wherein said nucleic acid-cationic immunoliposome complex is prepared by a method comprising:
- a) preparing said antibody fragment;
- b) directly conjugating said antibody fragment to said cationic liposome to form a cationic immunoliposome, wherein said conjugation occurs via a sulfur atom which was part of a sulfhydryl group at the carboxy terminus on said antibody fragment prior to said conjugation;
- and
- c) mixing said cationic immunoliposome with said nucleic acid to form said nucleic acid-cationic immunoliposome complex;
- wherein said antibody fragment and said cationic liposome are present at a protein:lipid ratio (w:w) in the range of 1:10 to 1:40 and wherein said nucleic acid and said cationic liposome are present at a nucleic acid:lipid (μg:nmol) ratio in the range of 1:6 to 1:20.
Dependencies are inferred from the claim text.